Curve Ahead Market Strategies

Friday November 1st - Mid-Morning 52 week high list

As our readers know we like to look at the 52 week high list on down days to create a list of stocks to begin our stock selection process but even more important is the 52 week high list during a series of down session coupled with an overall weak mont

Short Term – Daily FOREX Analysis – November 1, 2013

EURUSD’s downward movement from 1.3832 extends to as low as 1.3539. Deeper decline to test 1.3462 support is possible, as long as this level holds, the fall could be treated as consolidation of the longer term uptrend from 1.2756 (Jul 9 low)

U.S. Stock Market

Early morning stocks that are trending in the U.S. pre-market this morning are:

CurveAheadMarketStrategies.com Morning Coffee Break

U.S. futures are riding yesterday’s momentum of positive U.S. economic data refueling speculation the Federal Reserve may opt to taper its $85 billion stimulus program sooner rather than later.

Starbucks falls - Time Buy or Time to Sell?

A whirlwind is pushing Starbucks’ (SBUX, quote) stock around in today’s session after yesterday’s earnings report and followup conference call. 

The FED delivers a lesson in VPA!

For intraday emini index traders, last nights FED meeting delivered a classic lesson in volume price analysis (VPA).

Mid-Morning 52 Week High List

As our readers know we like to look at the 52 week high list on down days to create a list of stocks to begin our stock selection process but even more important is the 52 week high list during a series of down session coupled with an overall weak month.

Short Term – Daily Forex Analysis – October 31, 2013

GBPUSD moves sideways in a trading range between 1.5894 and 1.6259. As long as 1.5894 support holds, the price action in the range could be treated as consolidation of the uptrend from 1.4813

CurveAheadMarketStrategies.com Morning Coffee Break

With the two day Federal Reserve meeting in the rearview mirror this morning markets are remain flat in the pre-market albeit the DOW and S&P 500 are tilted to the down side. 

GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy

London, UK; 18 September 2013: GW Pharmaceuticals plc (GWPH) announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.